

Taking full advantage of the SEND data potential

Dragomir Draganov', Stefano Gaudio', Jean-Pierre Kieffer'', Matthias Festag', Pierre Maliver', Karuna Polavarapu''', Raja T. Ramesh''' 'pRED Pharmaceutical Sciences, "pRED Informatics, F. Hoffmann-La Roche Ltd. Switzerland, "PointCross Life Sciences Inc.

1 – Introduction

Establishing robust processes for SEND data package preparation for regulatory submissions to FDA present great challenges for the Industry, but created the opportunity of having digitized, machine readable, highly standardized study data for search, exploration, comparison across studies and analysis. In this poster, we present our current experiences in utilizing SEND data for three main business cases:

1) Improving efficiency of study monitoring with access to "real time" data for ongoing studies. For this purpose, we developed a fully automated workflow covering data



acquisition, transfer and database upload.

2) Simultaneous review of [audited] draft reports with accompanying complete SEND data packages. Efficient report review and reconciliation while verifying the fitness, consistency, completeness and accuracy of the SEND data.

3) Cross-study analysis to facilitate data interpretation and gaining insights across individual studies or submission package(s).

The three use cases are supported by a single User Interface dubbed RoDEo.

2 Safety Data Integration (SDI) Database & RoDEo Tool



The Safety Data Integration (SDI) database holds data from a large number of non-clinical studies performed in-house or at CROs, including recent studies in SEND format and legacy studies not in SEND format. All data is mapped to Universal Data Model (**UDM**) containing harmonized, invariant terminology and units across studies. Data in SDI can be searched, accessed and extracted using different user interfaces (UIs). RoDEo (Roche Data Exploration) is a new UI specifically developed for visualization of data in SEND format with user-friendly and intuitive graphical and tabulation capabilities as illustrated in the figures below.

RoDEo Navigation Panel

Team Space Features



> Automated updates of figures & tables with new uploads.

Clinical signs of toxicity; Dose-dependency of onset &/or severity of findings; Decisions on changes in study design (dose adjustment or holiday); Dose selection for fixed-dose phase based on MTD.

4 – Facilitation of draft report review



- Complete draft SEND package available with Audited Draft Report;
- Easy access to summary & individual data;
- Create custom cohorts across study data;
- \succ "Deep dive" on subject &/or finding level;
- Visualizations created during in-life phase available on Team Space with annotations & comments.

Are the findings, interpretations, conclusions in draft report supported by the raw data? Are there new observations, interpretation, conclusions from SEND data analysis not reflected in the draft report?

Exploration of findings-driven cohorts including quantitative or qualitative findings.

Is the SEND dataset fit for purpose – can the data be plotted & tabulated as expected? Are there any discrepancies between the SEND data & results presented in the draft report? If yes, **reconciliation** process is initiated.

5 – Cross study analysis



Highlights of Numeric Data Visualizations



Highlights of Categorical Data Visualizations

	oDEo <u>LWish User Guide</u> Histopath												III RoDEo LWish User Guide						
1	🏠 🗘 Sponsor Group 👻 🕂 Cohort	Viev	vs 👻 Microscopic Findings							🖺 s	ave to TFL Libra	ry 🗄 Con	solidated View		~	Sponsor Gro	up = 🕇 Cohort		Views
	Consolidated Histopath view	Ø				Male				Female					Day (s):	,	Navigator		G
	Show Days Color Gradient (Relative Incidence %) 0 1-20 21-40 41-60 61-80 81-100		⊡ Tissue (Findings)	Modifiers	Severity	1: 0 mg/kg Group 1	2: 10 mg/kg Group 2	3: 30 mg/kg Group 3	4: 100 mg/kg Group 4	1: 0 mg/kg Group 1	2: 10 mg/kg Group 2	3: 30 mg/kg Group 3	4: 100 mg/kg Group 4		Rela 0	Male tive Incidence(%):	Z Female	. 100	
	Search	Q	Liver		#Examined	5	5	5	5	5	5	5	5		0	•		. 1	
	Microscopic Findings		DEGENERATION/NECROSIS	hepatocellular	2 Of 5	0					1		0		Orga	ins / Tissues:			
		\sim	DEGENERATION/NECROSIS	hepatocellular	4 Of 5	0	Hypo	rlink	to all	onim		ith thi	ic		Lh	rer ×			*
	Brain		DEGENERATION/NECROSIS		Total	0	Type	IIIIK	iu all	amm	iais w		15		Plan Orga	ned Tissues /	*		
	Mesenteric Lymph Node		HYPERTROPHY/HYPERPLASIA	kupffer cell	1 Of 5	0	findir	nd and	d sev	eritv					Find	ings: Meroscopic Findings	p		
			HYPERTROPHY/HYPERPLASIA	kupffer cell	2 Of 5	0									Line 10 Line 1				
	Injection Site		HYPERTROPHY/HYPERPLASIA		Total	0	2	0	1		2	1	0			Field		Internet	
	Submandibular Lymph Node		Increased cellularity	sinusoid	1 Of 5	0	0	_			Ontoits			8	Dosa	ige gi	Liver 30 Liver 31 MCROSIS 1.0		
	Spleen		Increased cellularity	sinusoid	2 Of 5	0	2 Sample or Standardte	tent	: Liver - soveresteroescologi	1001 1111					Seve	erity: Machine Star 25	Harrison Day 25 Aparts	new Marrier, Farmer 17 semanet celularity 15	200 5
	- Tonsil		Increased cellularity		Total	0	2 Sizx Croup Descrip	-	Lun	seliele	to C	ubio o	+ Drofile	View					
	Gut-Associated Lymphoid Tissue		Infiltration, mixed cell		1 Of 5	0	0 GEPDESC	USURI	пуре	эппк	10 51	plec	Fiolite	view		Imposion Sile 25 Initiation, mixed cell 11	Nandarn Argenten 1 Popular billione 1	increased collabority 11	Taute 13 March 71,007
	- Heart		Infiltration, mixed cell		Total	0	2 10 mg/tg 0 2 10 mg/tg 0	Dresp 2 PCR 1037 Dresp 2 PCR 1037	1102-3082 kup/fer	cell Non-Necpli	astic Disorder astic Disorder	20 U 31 P		Moribund Sa Terminal Sak		from 25 Initiation manenaction cal	D MERAL OL	annen 38 november 18 den 19 den	1.2M
	Lung		Infiltration, mononuclear cell		1.015	4	2												A Dens Or





- Search SDI by user-defined criteria:
 - Same compound, different duration or species;
 - Studies with a particular finding, eg, clinical parameters within a certain range;
 - Historical controls data;
 - Create custom cohorts across studies in an iterative manner;
 - Visualizations created during cross-study analysis available on Team Space with annotations & comments.

Data exploration: Are specific findings related to a compound consistent across studies? Is their appearance dose & time related? Do they correlated with other findings? Are there species &/or gender differences? Hypothesis testing: Do data from the cross-study analysis support or reject given

hypothesis for compound/ dose-related findings; causality?

6 – Conclusions

In the examples provided in this poster, a custom UI developed specifically for SEND data exploration and analysis was successfully employed to explore and analyze SEND-like or non-SEND data sets (extracts from LIMS and legacy studies, respectively) by mapping to an UDM and applying harmonized terminology. This allowes efficient data utilization from ongoing studies, along with cross study analysis for ongoing and completed studies, regardless of their SEND status.

Acknowledgments

SDI is supported by Xbiom 3.1 software developed by PointCross Life Sciences Inc. RoDEo is an enhanced and customized UI developed in close collaboration between Roche and PointCross based on the

Immersive Graphic Object (IGO) application. This collaboration was sponsored by internal Roche pREDi grants: SDI Enhancements (2019) and Non Clinical Study Data FAIRification (2020).

The authors would like to acknowledge the ideas, feedback and contribution of many colleagues at both

companies during the development, testing and employment of RoDEo and SDI enhancements.